What MagQu does

MagQu Co., Ltd. (磁量生技股份有限公司) is a Taiwan-based, privately held biotechnology company founded in 2008 and headquartered in New Taipei City. The company develops and commercializes ImmunoMagnetic Reduction (IMR) technology — an ultra-sensitive bioassay platform that uses functionalized Fe3O4 magnetic nanoparticles conjugated with antibodies to bind target biomarkers, with quantification achieved by measuring changes in AC magnetic susceptibility using a Superconducting Quantum Interference Device (SQUID) detector. MagQu claims to have developed the world's first CE-IVD certified Alzheimer's disease blood test, with three core IMR reagent products (Amyloid β 1-40, Amyloid β 1-42, and Tau protein) plus supporting analyzers (XacPro-S, MagQuan V, XacQuan V), magnetic beads, nucleic acid extraction kits, and OEM/ODM services. The platform is positioned as a non-invasive alternative to spinal taps and PET imaging for early Alzheimer's detection, with claimed picomolar-level sensitivity (1-200 pg/mL for Aβ1-40; 1-100 pg/mL for Aβ1-42 and Tau) and 5-hour turnaround.

The company's primary customer segments are healthcare providers and clinical research institutions, served through direct institutional sales in Taiwan and through channel/distribution partnerships in Europe and the United States. Revenue is generated through IVD reagent kit sales, analyzer/instrument hardware sales, magnetic bead and separator sales, OEM/ODM services for kits and instruments, and contract magnetic concentration measurement services. Pricing is quote-based and not publicly disclosed. Clinical validation has been conducted through partnerships with four major Taiwanese medical centers (National Taiwan University Hospital, Shuang Ho Hospital, Renai Hospital, En Chu Kong Hospital) covering 400+ Phase II/III patient cases with reported 80% diagnostic accuracy. International commercial expansion is enabled by CE-IVD certification and channel relationships with European biotech partners, UK-based Cerba Research, US-based St. Joseph's Hospital and Medical Center, and Arizona State University. The company holds more than 50 granted patents across North America, Japan, the EU, China, and Taiwan covering the core IMR platform, magnetic bead conjugation chemistry, and specific biomarker reagent formulations.

Name

MagQu

Legal name

MagQu Co. Ltd

Website

https://magqu.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

MagQu is a Taiwan-based biotechnology company that develops ultra-sensitive blood-based diagnostic tests using proprietary ImmunoMagnetic Reduction (IMR) and SQUID detection technology, primarily serving hospitals, clinical research institutions, and diagnostic laboratories in Alzheimer's disease, oncology, and life science research markets.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD) and Immunoassay Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

Keywords

• In vitro diagnostics
• Immunoassay reagents
• Magnetic susceptibility analysis
• Alzheimer's blood test
• SQUID bioassay instruments

Headquarters

HQ city

New City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

1. IVD Reagent Sales: Sale of IMR reagent kits for detecting specific biomarkers including Aβ1-40, Aβ1-42, Tau protein, AFP, and CEA. Sold in kit format with catalog numbers (e.g., MF-AB0-006B, MF-AB2-006B, MF-TAU-006B) for clinical and research use.
2. Analyzer/Instrument Sales: Sale of magnetic immunoassay analyzers (XacPro-S, MagQuan V, XacQuan V) and magnetic separators (Magdorf). Instruments provide the platform for running IMR assays.
3. Magnetic Beads and Separators: Sale of magnetic beads (Qbeads-Carboxyl, Magnetic Fluid-Carboxyl) and magnetic separators for research and diagnostic applications. Includes labeling kits for custom conjugation.
4. Customized Instrument OEM/ODM Services: Instrument customization services and OEM/ODM for IMR assay kit development, magnetic beads development, and antibody manufacturing for partners.
5. Magnetic Concentration Quantification Service: Contract testing services for magnetic concentration measurements using proprietary analyzers.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

MagQu develops, manufactures, and sells in-vitro diagnostic (IVD) reagent kits and analyzer instruments built on its proprietary ImmunoMagnetic Reduction (IMR) platform for ultra-sensitive detection of blood biomarkers, including Aβ1-40, Aβ1-42, and Tau protein for early Alzheimer's disease diagnosis. The product portfolio includes CE-IVD and Taiwan FDA-cleared reagent kits, SQUID-based Magnetic Immunoassay Analyzers, magnetic concentration analyzers, functionalized magnetic beads, magnetic separators, and nucleic acid extraction kits sold directly to hospitals, research institutions, and diagnostic laboratories. Custom OEM/ODM services and contract magnetic concentration quantification services supplement the product offering.

Product overview

MagQu is a biotechnology company specializing in ImmunoMagnetic Reduction (IMR) technology for ultra-sensitive biomarker detection. The product portfolio consists of: (1) Analyzer instruments including the XacPro-S SQUID-based Magnetic Immunoassay Analyzer for clinical IMR measurements, the MagQuan V rapid magnetic concentration analyzer (30 sec/sample), and the XacQuan V frequency-dependent magnetic susceptibility analyzer (50-24900 Hz bandwidth); (2) IMR Reagents including Amyloid β 1-40, Amyloid β 1-42, and Tau Protein reagents for Alzheimer's disease diagnosis, with CE-IVD and Taiwan FDA certifications; (3) Magnetic beads including Qbeads-Carboxyl (~1 μm) and Magnetic Fluid-Carboxyl nanoparticles (50-60 nm) for molecular conjugation; (4) Supporting products including the Magdorf 8-well magnetic separator, Blood gDNA Extraction Kit, Virus DNA/RNA Extraction Kit, Cell Nucleic Acid Extraction Kit, and Qbeads-Carboxyl Labeling Kit. The IMR platform works by conjugating detection antibodies to Fe3O4 magnetic nanoparticles, which form clusters upon binding target biomarkers, reducing AC magnetic susceptibility in proportion to biomarker concentration.

Differentiator

Problem solved

Functional benefit

Products and services

• XacPro-S Magnetic Immunoassay Analyzer SQUID-based immunoassay analyzer that measures AC magnetic susceptibility for IMR bioassays, enabling ultra-high-sensitivity quantification of biomarkers such as Aβ1-40, Aβ1-42, and Tau protein in human fluid specimens. Designed for clinical and research laboratories running MagQu's IMR reagent portfolio.
• MagQuan V Magnetic Concentration Analyzer Rapid magnetic concentration measurement instrument that measures AC magnetization intensity for samples at roughly 30 seconds per sample, covering solid and liquid samples with volumes up to 5 mL without pretreatment. Used by industrial, materials, and research customers for fast magnetic concentration analysis.
• XacQuan V Frequency-Dependent Magnetic Susceptibility Analyzer Frequency-dependent magnetic susceptibility analyzer that measures real and imaginary components of AC magnetic susceptibility across a 50–24900 Hz bandwidth for analyzing magnetic concentration and material properties. Targeted at industrial QC, materials research, and life science research laboratories.
• MagQu Amyloid β 1-40 (Aβ1-40) IMR Reagent ImmunoMagnetic Reduction reagent (MF-AB0-006B) for quantitative detection of Amyloid β 1-40 protein in human plasma with an analytical range of 1–200 pg/mL. Uses ~50 nm Fe3O4 magnetic particles conjugated with anti-Aβ1-40 antibodies; assists in the diagnosis of Alzheimer's disease. CE-IVD and Taiwan FDA cleared for IVD use.
• MagQu Amyloid β 1-42 (Aβ1-42) IMR Reagent ImmunoMagnetic Reduction reagent (MF-AB2-006B) for quantitative detection of Amyloid β 1-42 protein in human plasma with an analytical range of 1–100 pg/mL. Designed to assist in the diagnosis of Alzheimer's disease by detecting a major component of amyloid plaques. CE-IVD and Taiwan FDA cleared for IVD use.
• MagQu Tau Protein IMR Reagent ImmunoMagnetic Reduction reagent (MF-TAU-006B) for quantitative detection of Tau protein in human plasma with an analytical range of 1–100 pg/mL. Associated with Alzheimer's, Pick's, Parkinson's, and other neurodegenerative conditions. CE-IVD and Taiwan FDA cleared for IVD use.
• Aβ1-40 Protein Control Solution Low and high concentration quality control solutions used as standards for MagQu's Aβ1-40 IMR Reagent (MF-AB0-006B). Supplied alongside the reagent as part of the clinical IMR assay workflow.
• Qbeads-Carboxyl Magnetic Beads Carboxyl-functionalized magnetic beads (~1 μm diameter) with a single-crystal Fe3O4 core and dextran coating, used for covalent conjugation of antibodies, proteins, peptides, or DNA via EDC activation. Sold to life science research laboratories for custom assay development.
• Magnetic Fluid-Carboxyl Nanoparticles Carboxyl-functionalized magnetic nanoparticles (50–60 nm diameter, 8 mg-Fe/mL concentration) with a dextran-coated Fe3O4 core, used for biospecies separation, biomedical imaging, and bioassay development. Supplied to research laboratories and OEM partners.
• Magdorf Magnetic Separator Eight-well magnetic separator for 1.5 mL microcentrifuge tubes providing strong magnetism for fast collection of micron-size magnetic beads, used in bead-based nucleic acid extraction and immunoprecipitation workflows in research labs.
• Blood gDNA Extraction Kit Manual genomic DNA extraction kit from blood samples using magnetic particles, providing high-yield, low-cost purified gDNA suitable for Real-Time PCR, PCR, and other molecular experiments. 96 reactions per kit, sold to research and clinical molecular laboratories.
• Virus DNA/RNA Extraction Kit (manual) Manual extraction kit for viral DNA or RNA from cell-free samples using magnetic particles, with DNA/RNA separable by user-added DNase or RNase. Marketed for in vitro diagnostic use by clinical and research laboratories.
• Cell Nucleic Acid Extraction Kit Manual extraction kit for total nucleic acids from cells using magnetic particles, yielding purified nucleic acids suitable for Real-Time PCR, PCR, and other molecular experiments. Sold to research laboratories.
• Qbeads-Carboxyl Labeling Kit Complete kit for covalently conjugating antibodies, peptides, or DNA with primary amine groups onto carboxyl-functionalized Qbeads, used for immunoprecipitation, chromatin immunoprecipitation, and pull-down assays in research laboratories.
• IMR Assay Kit OEM/ODM Customization Service OEM/ODM customization services for IMR assay kit development, enabling partners to leverage MagQu's IMR platform for their own biomarker assays. Sold to diagnostic and biotech partners.
• Magnetic Beads OEM/ODM Development Service Custom development of functionalized magnetic beads for OEM/ODM partners, including bead design, surface chemistry, and application-specific conjugation services. Sold to life science and diagnostic partners.
• Antibody OEM/ODM Service Custom antibody manufacturing and OEM/ODM antibody services for partners, supporting IMR assay and magnetic bead development workflows. Sold to diagnostic and research partners.
• Magnetic Concentration Quantification Service Contract magnetic concentration measurement service performed by MagQu on customer samples using MagQu's proprietary analyzers, including applications such as lubricant iron content monitoring, magnetic fluid concentration, and steel/powder metallurgy QC. Sold to industrial and research customers.
• Instrument Customization Service Instrument customization services adapting MagQu's XacPro-S, MagQuan V, XacQuan V, and Magdorf platforms for partner-specific analytical workflows. Sold to OEM/ODM partners and large institutional customers.

Quantifiable outcome

• 80% clinical accuracy in distinguishing mild cognitive impairment and early Alzheimer's disease patients
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• Cerba Research (UK)coreStrategic or Co-development Partner · 1 July 2021Cerba Research, a UK-based clinical research organization, acknowledged the efficacy of MagQu's immunomagnetic reduction (IMR) blood test for diagnosing early Alzheimer's disease in July 2021. The partnership focuses on developing blood-based biomarkers for early diagnosis of Alzheimer's disease, with reference to published studies showing elevated plasma Aβ42 and t-tau levels correlate with later cognitive decline in patients with mild cognitive impairment.
• European Biotech/Medical Partners (Continental Europe)coreChannel Partner/ Reseller/ DistributorStrategic collaboration with European biotech and medical companies for market entry into continental Europe. The partnership leverages MagQu's CE-IVD certified Alzheimer's blood test products to serve the European clinical diagnostics market. This followed recognition as the world's first CE-IVD certified Alzheimer's blood test and significant international attention from US, European, and Japanese pharmaceutical companies seeking clinical research and commercial partnerships.
• St. Joseph's Hospital and Medical Center (USA)coreStrategic or Co-development PartnerUS clinical application partnership for neurodegenerative disease blood testing, including development and validation of IMR-based diagnostics in a clinical setting. Plans include establishment of a CLIA-certified reference laboratory for providing IMR blood test services in the US market.
• Arizona State University (USA)coreStrategic or Co-development PartnerAcademic research collaboration with Arizona State University for clinical research partnerships and application development of neurodegenerative disease blood tests. ASU's research capabilities complement MagQu's IMR technology platform for advancing Alzheimer's disease diagnostics.
• National Taiwan University Hospital, Shuang Ho Hospital, Renai Hospital, En Chu Kong HospitalcoreStrategic or Co-development PartnerClinical trial partnerships with major Taiwanese medical institutions for validation of Alzheimer's disease blood screening platform. Completed Phase II and Phase III clinical trials involving 400+ patient cases, achieving 80% diagnostic accuracy. Results supported Taiwan FDA (TFDA) registration applications for Class III medical device approval.

Scale indicators6 records

Emerging players

• PerkinElmer: PerkinElmer's diagnostics and life sciences segments provide biomarker detection reagents and instruments overlapping with MagQu's analyzer and reagent portfolio, particularly in clinical and translational research.
• ADx NeuroSciences: ADx NeuroSciences develops and licenses high-quality Alzheimer's biomarker antibodies and assays, overlapping with MagQu's IMR reagent portfolio as a focused emerging player in neurodegeneration diagnostics.

Broad incumbents

• Roche Diagnostics: Roche's Elecsys Alzheimer's disease plasma assays (pTau217, Aβ42) run on the globally installed cobas analyzer base, representing a much larger-scale incumbent that MagQu would compete against for hospital adoption.
• Siemens Healthineers: Siemens' ADVIA Centaur and Atellica immunoassay platforms address Alzheimer's and oncology biomarker testing through a global installed base, overlapping with MagQu's clinical diagnostic use cases.
• Bio-Techne: Bio-Techne offers protein biomarker assay kits and magnetic bead-based research reagents through its ProteinSimple and R&D Systems brands, overlapping with MagQu's life-science research and IMR reagent offerings.
• Abbott Diagnostics: Abbott's ARCHITECT and Alinity immunoassay systems run biomarker panels relevant to neurodegeneration and oncology, representing broad incumbent competition for clinical diagnostic menu share.

Direct peers

• C2N Diagnostics: C2N's PrecivityAD blood test for Alzheimer's diagnosis is the most direct US-market competitor, and its CLIA-certified reference lab service model parallels MagQu's planned St. Joseph's CLIA partnership strategy.
• Quanterix: Quanterix's Simoa single-molecule array technology provides ultra-sensitive blood-based biomarker detection, directly comparable to MagQu's IMR platform in pursuit of picomolar-level quantification of neurodegeneration and oncology biomarkers.
• Fujirebio: Fujirebio's Lumipulse G pTau217/β-amyloid 1-42 plasma assays are FDA-cleared blood-based Alzheimer's diagnostics with overlapping biomarker menu and clinical positioning to MagQu's CE-IVD Alzheimer's reagents.

Regional players

• Sysmex: Sysmex is a Japan-headquartered diagnostics and life-sciences company with strong Asia-Pacific distribution and a hematology/immunoassay footprint relevant to MagQu's Japan presence and broader Asian commercial strategy.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/magqucoltd
• Facebookfacebook.com/magquIMR

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MagQu